GlassScriptPhysician profile
Colby Meuleman
NPI 1629732102
$3,999.08
in general payments reported to CMS, 2019-2025
28 companies · $3,061 in 2025
The $3,061 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $938 · 2025: $3,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807 · Travel and Lodging: $959 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,807.00 |
| Travel and Lodging | $959.14 |
| Education | $232.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,393.91 | 2024-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $413.87 | 2024-2025 | |
| Harmony Biosciences LLC | $362.39 | 2024-2025 | |
| Glaxosmithkline, LLC. | $234.20 | 2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $174.64 | 2025 | Airsupra, Tezspire, Breztri |
| Genzyme Corporation | $171.95 | 2025 | |
| Baxter Healthcare | $171.48 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Avadel Cns Pharmaceuticals, LLC | $140.46 | 2024-2025 | Lumryz |
| W. L. Gore & Associates, INC. | $115.55 | 2024 | Gore Enform Preperitoneal Biomaterial |
| Mylan Specialty L.P. | $90.92 | 2024 | Yupelri |
| Philips North America LLC | $86.13 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| United Therapeutics Corporation | $77.62 | 2025 | Tyvaso |
| Viatris Specialty LLC | $76.05 | 2025 | Yupelri |
| Insmed, INC. | $60.75 | 2025 | Brinsupri, Arikayce |
| Grifols USA, LLC | $58.04 | 2024-2025 | Prolastin-C Liquid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $56.51 | 2025 | Sunosi |
| Genentech USA, INC. | $49.36 | 2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $45.41 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $38.54 | 2025 | Zepbound |
| Verona Pharma, INC. | $36.62 | 2025 | Ohtuvayre |
| Inogen, INC. | $23.22 | 2024 | |
| Liquidia Technologies, INC. | $20.57 | 2025 | Yutrepia |
| Ani Pharmaceuticals, INC. | $20.17 | 2024 | Purified Cortrophin Gel |
| Pfizer INC. | $18.79 | 2024 | |
| La Jolla Pharmaceutical Company | $18.64 | 2025 | Giapreza |
| Alexion Pharmaceuticals, INC. | $15.73 | 2025 | Ultomiris |
| Phadia US INC. | $13.96 | 2024 | Immunocap |
| Electromed, INC. | $13.60 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colby Meuleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.